StemRIM (4599.T)
JPY 298.0
(0.0%)
JPY 298.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 187 Million JPY | -44.68% |
| 2023 | 336.02 Million JPY | 74.62% |
| 2022 | 192.43 Million JPY | -9.5% |
| 2021 | 212.63 Million JPY | -50.71% |
| 2020 | 431.36 Million JPY | 369.1% |
| 2019 | 91.95 Million JPY | 74.76% |
| 2018 | 52.61 Million JPY | 0.49% |
| 2017 | 52.36 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 242.67 Million JPY | 2.27% |
| 2024 Q1 | 237.28 Million JPY | -29.39% |
| 2024 Q4 | 187 Million JPY | -12.4% |
| 2024 Q3 | 212.2 Million JPY | -12.56% |
| 2023 Q3 | 372.65 Million JPY | 76.48% |
| 2023 Q2 | 211.16 Million JPY | -5.6% |
| 2023 Q4 | 336.02 Million JPY | -9.83% |
| 2023 Q1 | 223.67 Million JPY | 16.24% |
| 2023 FY | 336.02 Million JPY | 74.62% |
| 2022 Q3 | 192.98 Million JPY | -0.77% |
| 2022 Q2 | 194.47 Million JPY | -3.75% |
| 2022 Q1 | 202.05 Million JPY | -4.98% |
| 2022 Q4 | 192.43 Million JPY | -0.29% |
| 2022 FY | 192.43 Million JPY | -9.5% |
| 2021 Q4 | 212.63 Million JPY | 0.65% |
| 2021 FY | 212.63 Million JPY | -50.71% |
| 2021 Q1 | 170.43 Million JPY | -60.49% |
| 2021 Q3 | 211.26 Million JPY | -40.78% |
| 2021 Q2 | 356.73 Million JPY | 109.3% |
| 2020 Q4 | 431.36 Million JPY | 529.73% |
| 2020 Q2 | 108.16 Million JPY | 50.55% |
| 2020 Q1 | 71.85 Million JPY | -21.86% |
| 2020 FY | 431.36 Million JPY | 369.1% |
| 2020 Q3 | 68.49 Million JPY | -36.67% |
| 2019 Q4 | 91.95 Million JPY | -23.04% |
| 2019 Q3 | 119.49 Million JPY | 0.0% |
| 2019 FY | 91.95 Million JPY | 74.76% |
| 2018 FY | 52.61 Million JPY | 0.49% |
| 2017 FY | 52.36 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 94.241% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -194.902% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.29% |
| Linical Co., Ltd. | 10.3 Billion JPY | 98.185% |
| Trans Genic Inc. | 3.81 Billion JPY | 95.095% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 68.316% |
| Soiken Holdings Inc. | 697.02 Million JPY | 73.172% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 93.809% |
| AnGes, Inc. | 2.78 Billion JPY | 93.296% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 63.591% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.793% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 47.066% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 88.666% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 60.411% |
| CanBas Co., Ltd. | 91.98 Million JPY | -103.287% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 82.901% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 76.909% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 68.504% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 95.604% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.358% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 66.99% |
| Ribomic Inc. | 155.8 Million JPY | -20.019% |
| SanBio Company Limited | 2.25 Billion JPY | 91.707% |
| Healios K.K. | 11.28 Billion JPY | 98.343% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 25.578% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 49.322% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 22.566% |
| CellSource Co., Ltd. | 677.73 Million JPY | 72.408% |
| FunPep Company Limited | 189.32 Million JPY | 1.228% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 68.674% |
| Stella Pharma Corporation | 1.44 Billion JPY | 87.046% |
| TMS Co., Ltd. | 97.68 Million JPY | -91.424% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -104.385% |
| Cuorips Inc. | 200.96 Million JPY | 6.947% |
| K Pharma,Inc. | 209.13 Million JPY | 10.584% |
| Takara Bio Inc. | 11.42 Billion JPY | 98.363% |
| ReproCELL Incorporated | 741.03 Million JPY | 74.765% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 79.623% |
| StemCell Institute Inc. | 3.85 Billion JPY | 95.143% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 79.415% |
| CellSeed Inc. | 301.04 Million JPY | 37.883% |